{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:15:15Z","timestamp":1786986915232,"version":"build-2736575974"},"reference-count":45,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.clbc.2021.01.009","type":"journal-article","created":{"date-parts":[[2021,1,23]],"date-time":"2021-01-23T11:22:12Z","timestamp":1611400932000},"page":"e434-e447","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Cutaneous Toxicities in Breast Cancer Patients Receiving Chemotherapy and Targeted Agents\u2013\u2013An Observational Clinical Study"],"prefix":"10.1016","volume":"21","author":[{"given":"T.M.","family":"Anoop","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rona","family":"Joseph P","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mini","family":"PN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranab","family":"KP","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gayatri","family":"Gopan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffi","family":"Chacko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2021.01.009_bib0001","first-page":"267","article-title":"Chemotherapy-induced dermatological toxicity: frequencies and impact on quality of life in women's cancers. Results of a prospective study","volume":"16","author":"Hackbarth","year":"2008","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clbc.2021.01.009_bib0002","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/pon.3531","article-title":"Impact of chemotherapy induced alopecia distress on body image, psychosocial well-being, and depression on breast cancer patients","volume":"23","author":"Choi","year":"2014","journal-title":"Psychooncology"},{"key":"10.1016\/j.clbc.2021.01.009_bib0003","article-title":"Restorative oncodermatology: diagnosis and management of dermatologic sequelae from cancer therapies","author":"Rossi","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clbc.2021.01.009_bib0004","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4103\/ijd.IJD_65_17","article-title":"Cutaneous adverse reactions of chemotherapy in cancer patients: a clinicoepidemiological study","volume":"63","author":"Biswal","year":"2018","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.clbc.2021.01.009_bib0005","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1684\/ejd.2016.2833","article-title":"Dermatological adverse events with taxane chemotherapy","volume":"26","author":"Sibaud","year":"2016","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.clbc.2021.01.009_bib0006","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1756-9966-31-50","article-title":"Chemotherapy and skin reactions","volume":"31","author":"Fabbrocini","year":"2012","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.clbc.2021.01.009_bib0007","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1200\/EDBK_289911","article-title":"Dermatologic adverse events of systemic anticancer therapies: cytotoxic chemotherapy, targeted therapy, and immunotherapy","volume":"40","author":"Deutsch","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.clbc.2021.01.009_bib0008","doi-asserted-by":"crossref","first-page":"554","DOI":"10.3109\/0284186X.2011.636755","article-title":"Hand and foot syndrome associated with docetaxel treatment","volume":"51","author":"Stravodimou","year":"2012","journal-title":"Acta Oncol"},{"key":"10.1016\/j.clbc.2021.01.009_bib0009","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.abd.2020.01.001","article-title":"Management of dermatologic adverse events from cancer therapies: recommendations of an expert panel","volume":"95","author":"Cury-Martins","year":"2020","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.clbc.2021.01.009_bib0010","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1001\/archderm.136.12.1475","article-title":"Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin","volume":"136","author":"Lotem","year":"2000","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clbc.2021.01.009_bib0011","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/j.1529-8019.2011.01435.x","article-title":"Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib","volume":"24","author":"McLellan","year":"2011","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.clbc.2021.01.009_bib0012","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0001-7310(08)74677-5","article-title":"Chemotherapy-induced acral erythema: a clinical and histopathologic study of 44 cases","volume":"99","author":"Hueso","year":"2008","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.clbc.2021.01.009_bib0013","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1001\/jama.2016.15865","article-title":"Effect of tailored dose-dense chemotherapy vs standard 3-weekly adjuvant chemotherapy on recurrence-free survival among women with high-risk early breast cancer: a randomized clinical trial","volume":"316","author":"Foukakis","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.clbc.2021.01.009_bib0014","doi-asserted-by":"crossref","first-page":"e72245","DOI":"10.1371\/journal.pone.0072245","article-title":"Pyridoxine for prevention of hand-foot syndrome caused by chemotherapy: a systematic review","volume":"8","author":"Chen","year":"2013","journal-title":"PLoS One"},{"issue":"Suppl 7","key":"10.1016\/j.clbc.2021.01.009_bib0015","doi-asserted-by":"crossref","first-page":"vii167","DOI":"10.1093\/annonc\/mds294","article-title":"Management of chemotherapy extravasation: ESMO-EONS clinical practice guidelines","volume":"23","author":"P\u00e9rez Fidalgo","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2021.01.009_bib0016","doi-asserted-by":"crossref","first-page":"434","DOI":"10.4103\/0378-6323.159950","article-title":"Dermatological adverse reactions to cancer chemotherapy","volume":"81","author":"Pavey","year":"2015","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.clbc.2021.01.009_bib0017","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1080\/02841860310022977","article-title":"Skin toxicity as a risk factor for major infections in breast cancer patients treated with docetaxel","volume":"43","author":"Poikonen","year":"2004","journal-title":"Acta Oncol"},{"key":"10.1016\/j.clbc.2021.01.009_bib0018","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jaad.2005.08.033","article-title":"An acneiform eruption due to erlotinib: Prognostic implications and management","volume":"54","author":"Journagan","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clbc.2021.01.009_bib0019","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3109\/15569527.2010.498397","article-title":"Docetaxel-induced acral erythema and nail changes distributed to photo exposed areas","volume":"29","author":"Ferreira","year":"2010","journal-title":"Cutan Ocul Toxicol"},{"issue":"2 Pt 2","key":"10.1016\/j.clbc.2021.01.009_bib0020","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0190-9622(98)70394-9","article-title":"Leg ulcers associated with long-term hydroxyurea therapy","volume":"39","author":"Weinlich","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clbc.2021.01.009_bib0021","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/j.1365-2133.1994.tb04986.x","article-title":"Bleomycin-induced flagellate dermatitis: a clinical and histopathological review","volume":"131","author":"Mowad","year":"1994","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clbc.2021.01.009_bib0022","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1093\/jnci\/95.5.410","article-title":"Re: folliculitis associated with weekly paclitaxel treatment","volume":"95","author":"Belda-Iniesta","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clbc.2021.01.009_bib0023","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/CAD.0000000000000032","article-title":"Life-threatening dermatologic adverse events in oncology","volume":"25","author":"Rosen","year":"2014","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.clbc.2021.01.009_bib0024","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1097\/00001813-200311000-00009","article-title":"Thrombotic microangiopathy and digital necrosis: two unrecognized toxicities of gemcitabine","volume":"14","author":"Venat-Bouvet","year":"2003","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.clbc.2021.01.009_bib0025","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1046\/j.1523-5394.2001.96007.x","article-title":"Psychological sequelae and alopecia among women with cancer","volume":"9","author":"McGarvey","year":"2001","journal-title":"Cancer Pract"},{"key":"10.1016\/j.clbc.2021.01.009_bib0026","first-page":"5","article-title":"Chemotherapy-induced Hair Loss","volume":"15","year":"2010","journal-title":"Skin Therapy Lett"},{"key":"10.1016\/j.clbc.2021.01.009_bib0027","doi-asserted-by":"crossref","first-page":"604","DOI":"10.4103\/0378-6323.116728","article-title":"Anagen effluvium","volume":"79","author":"Kanwar","year":"2013","journal-title":"Indian J Dermatol Venerol Leprol"},{"key":"10.1016\/j.clbc.2021.01.009_bib0028","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.jaad.2018.03.056","article-title":"Hair disorders in cancer survivors","volume":"80","author":"Freites-Martinez","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clbc.2021.01.009_bib0029","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.clbc.2017.07.012","article-title":"Scalp hypothermia for preventing alopecia during chemotherapy. a systematic review and meta-analysis of randomized controlled trials","volume":"18","author":"Rugo","year":"2018","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.clbc.2021.01.009_bib0030","first-page":"799","article-title":"Tamoxifen-induced hirsutism","volume":"10","author":"Al-Niaimi","year":"2011","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.clbc.2021.01.009_bib0031","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-2125.2008.03174.x","article-title":"Nail and periungual toxicity following capecitabine therapy","volume":"66","author":"Vaccaro","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clbc.2021.01.009_bib0032","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ijwd.2019.10.003","article-title":"Dermatologic conditions in women receiving systemic cancer therapy","volume":"5","author":"Ferreira","year":"2019","journal-title":"Int J Women's Dermatol"},{"key":"10.1016\/j.clbc.2021.01.009_bib0033","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/bjd.13743","article-title":"The risk of nail changes with taxane chemotherapy: a systematic review of the literature and meta-analysis","volume":"173","author":"Capriotti","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clbc.2021.01.009_bib0034","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1365-2230.2008.02928.x","article-title":"Acute paronychia caused by lapatinib therapy","volume":"34","author":"Rigopoulos","year":"2009","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.clbc.2021.01.009_bib0035","doi-asserted-by":"crossref","first-page":"e181","DOI":"10.1016\/S1470-2045(14)71133-7","article-title":"Nail toxicities induced by systemic anticancer agents","volume":"16","author":"Sibaud","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2021.01.009_bib0036","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/cncr.23333","article-title":"Matched case-control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel-induced onycholysis and cutaneous toxicity of the foot","volume":"112","author":"Scotte","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.clbc.2021.01.009_bib0037","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2165\/00128071-200607010-00005","article-title":"Cutaneous reactions to chemotherapy and their management","volume":"7","author":"Wyatt","year":"2006","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.clbc.2021.01.009_bib0038","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1159\/000497232","article-title":"Prophylaxis and management of skin toxicities","volume":"14","author":"Salzmann","year":"2019","journal-title":"Breast Care"},{"key":"10.1016\/j.clbc.2021.01.009_bib0039","doi-asserted-by":"crossref","first-page":"5542","DOI":"10.1200\/JCO.2005.02.027","article-title":"Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer","volume":"23","author":"Jones","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2021.01.009_bib0040","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1097\/00007611-197912000-00040","article-title":"Pigmentation of the tongue and mucous membranes associated with cancer chemotherapy","volume":"72","author":"Krutchik","year":"1979","journal-title":"South Med J"},{"key":"10.1016\/j.clbc.2021.01.009_bib0041","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1542\/peds.47.5.911","article-title":"Ichthyosis and methotrexate: a word of caution","volume":"47","author":"Jetton","year":"1971","journal-title":"Pediatrics"},{"key":"10.1016\/j.clbc.2021.01.009_bib0042","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S0002-9343(02)01163-4","article-title":"The epidemiology of peripheral vein infusion thrombophlebitis: a critical review","volume":"113","author":"Tagalakis","year":"2002","journal-title":"Am J Med"},{"key":"10.1016\/j.clbc.2021.01.009_bib0043","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1159\/000336772","article-title":"A search for predictive factors for hypersensitivity reactions to paclitaxel and platinum salts in chemotherapy for gynecologic pelvic neoplasms","volume":"74","author":"Piovano","year":"2012","journal-title":"Gynecol Obstet Invest"},{"key":"10.1016\/j.clbc.2021.01.009_bib0044","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","article-title":"Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy","volume":"19","author":"Sibaud","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.clbc.2021.01.009_bib0045","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ctrv.2017.05.003","article-title":"Combined immune checkpoint blockade (anti-PD-1\/anti-CTLA-4): evaluation and management of adverse drug reactions","volume":"57","author":"Hassel","year":"2017","journal-title":"Cancer Treat Rev"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820921000215?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820921000215?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:22:58Z","timestamp":1761513778000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820921000215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S1526820921000215"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2021.01.009","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cutaneous Toxicities in Breast Cancer Patients Receiving Chemotherapy and Targeted Agents\u2013\u2013An Observational Clinical Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2021.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}